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Introduction
Parkinson's disease (PD) is a neurodegenerative disease that affects about 3% of the population over 65 years of age. PD is characterized by a selective loss of dopaminergic neurons accompanied by movement disorders, including rigidity, bradykinesia, akinesia, tremors, and postural instability (Kalia and Lang, 2015; Poewe et al., 2017) . A non-human primate (NHP) PD model that mimics human PD is needed to develop an effective treatment strategy. NHP models that maintain stable chronic PD symptoms are essential to creating a translational study of the mechanisms underlying PD pathogenesis and the development of therapeutic agents (Emborg, 2007) .
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is used to reproduce essential symptoms of PD in NHPs, which possess a higher similarity to human patients with PD than do other animals (Blandini and Armentero, 2012; Morin et al., 2014; Porras et al., 2012; Przedborski et al., 2001) .
Recent research has reported that the dopaminergic neuronal systems in the substantia nigra pars compacta (SNpc) and the striatum were damaged by MPTP treatment, according to positron emission tomography (PET) imaging (Ashkan et al., 2007; Liu et al., 2014; Nagai et al., 2007) .
Although MPTP-induced NHP models have been widely investigated, their high rates of symptomatic variation are problematic for developing treatments.
A recent review provided guidelines regarding individual adjustments of MPTP treatment in order to reproduce stable chronic PD symptoms in macaques (Potts et al., 2014) . These authors demonstrated that stable NHP PD models require individual adjustments of MPTP according to the severity of behavioral symptoms. This indicates that the adjustment of the frequency of injections could be an important factor in controlling compensatory mechanisms.
However, it is still difficult to develop MPTP-induced chronic NHP models with stable symptoms, and the compensatory mechanisms underlying recovery of Parkinsonism after MPTP administration are unknown (Beaudoin-Gobert et al., 2015; Boulet et al., 2008; Bubak et al., 2015;  A C C E P T E D M A N U S C R I P T Jan et al., 2000; Lin et al., 2015; Mounayar et al., 2007) .
There are insufficient guidelines regarding the objective severity criteria of individual behavioral symptoms for adjustments of MPTP treatment. Because the neurological rating, a commonly used set of criteria, can potentially be affected by idiosyncrasies within each observer's subjective judgment (Imbert et al., 2000; Schneider and Kovelowski, 1990; Smith et al., 1993) , it is necessary to determine objective criteria that reflects individual severity of PD symptoms in order to calculate adjustments for MPTP treatment. In a recent studies, automatic video image analysis system was verified as a sensitive method of objective measurement for locomotion behavior in parkinsonian cynomolgus monkeys (Liu et al., 2009) . And, automatic video image analyzer systems were used to measure behavioral quantification for the PD models of cynomolgus induced by MPTP. However, there were no presented objective criteria for the individual severity of adjustments of MPTP (Durand et al., 2015; Grabli et al., 2013; Kikuchi et al., 2017; Mounayar et al., 2007) . Therefore, we hypothesized that individual adjustments of MPTP administration based on results of an automatic video-based analysis system were needed to resolve problems to develop MPTP-PD model. Automatic quantification of global activity (GA) using a video-based analysis system served as the objective criteria to evaluate Parkinsonian symptoms, because it analyzes bradykinesia, hypokinesia, and akinesia, and does not rely on subjective analysis. The GA is measured using SMART 3.0 software that is commonly used for rodents. The output was analyzed by counting the change rate of all pixels between sequential binary images, which were converted from frames of captured video images with a fixed home cage background (Khroyan et al., 2007; Otero et al., 2010; Toll et al., 2009 ). This method to generate binary images using captured video images with respect to spontaneous behavior in individual home cages is an advanced method compared to the previous method, which used the distinctive cages that with a screen device from direct light (Kikuchi et al., 2017) .
In this study, we aimed to develop a MPTP-induced chronic NHP model with stable symptoms by adjusting MPTP treatment based on individual behavioral quantification using a video-based analysis system. To validate this strategy, we assessed a Parkinsonian behavior score (Imbert et al., 2000; Kurlan et al., 1991) , an immunohistochemistry Western blot, and PET imaging of dopamine transporter (DAT) with [ 18 F] N-(3-fluoropropyl)-2ß-carboxymethoxy-3β-(4-
Material and methods

Experimental animals
Nine adult female cynomolgus monkeys (Macaca fascicularis) were used in this study (Table 1) . The monkeys originated from the Zhaoqing Laboratory Animal Research Centre (Guangdong Province, China) and were maintained in individual indoor cages at the National Primate Research Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB), as reported previously (Lee et al., 2014; Yeo et al., 2015) . The experimental animals were housed in cages that faced each other in double columns. The animals had visual and vocal interaction with their neighbors without physical contact to avoid injury to other individuals because of the excretion of MPTP metabolites. The dimensions of the cages are 60 cm × 80 cm × 80 cm. These cage spaces meet the guidelines of the National Institutes of Health in the USA.
They were restrictively fed commercial monkey chow (Harlan, USA) supplemented by various fruits and were given water ad libitum. They were also supplied with various rubber and plastic toys and fruits for enrichment. If the monkeys did not have an interest in a particular toy, new toys of different shapes and sizes were provided. Environmental conditions were maintained a temperature of 24 ± 2 degrees Celsius, a relative humidity of 50 ± 5%, and a 12 h light/12 h dark cycle. The attending veterinarian monitored the monkeys' health in accordance with the recommendations of the Weatherall report on the use of nonhuman primates in research (Weatherall, 2006) . They were specific pathogen free (B virus, simian retrovirus, simian immunodeficiency virus, simian virus 40, and simian T-cell lymphotropic virus). It was confirmed prior to this study. All procedures were approved by the KRIBB Institutional Animal Care and Use Committee (Approval No. KRIBB-AEC-16068). All animal experiments complied with the ARRIVE guidelines (Kilkenny et al., 2010) . Figure 1A . Five monkeys of the MPTP injected group (C1, C2, C3, C4, C5) and three monkeys of the saline injected group (C7, C8, C9) were used. The total dose of MPTP was commensurate with each individual animal's GA intensity. The stop point thresholds for MPTP administration were indicated by a GA intensity lower than 8% (arbitrary) of baseline intensity. In contrast, one monkey (C6) was discontinued injections before the threshold was reached.
Video recording
Data regarding the spontaneous behavior in individual home cages was collected using a high-resolution portable digital video camera (HDR-CX405, Sony Corp., Japan) fixed on a tripod 3 meters in front of home cage (Fig. 1B) . The monkeys were habituated to the recording system once a week for 2 months before the experiment. To prevent disturbance to the monkeys, no person was in the room while the camera was recording. Once a week total of 4 h of behavior was recorded consecutively (12:00-4:00 p.m.) for each monkey. 
Parkinsonian behavior assessment
The behavior of the monkeys was evaluated according to a rating scale for monkey PD models through analysis of video recordings conducted in 5 min periods every 60 min for a total duration of 240 min score using the Kurlan scale (Imbert et al., 2000; Kurlan et al., 1991) . This scale rates 10 parkinsonian motor symptoms: facial expression (0-3); resting tremor (0-3); action or intention tremor (0-3); posture (0-2); gait (0-3); bradykinesia (0-4); balance coordination (0-3); gross motor skills of upper limb (0-3) and lower limb (0-3), and defense reaction (0-2). The minimum score is 0, which indicates a normal degree of movement, and the maximum total score is 29. To prevent subjective biases, the evaluation was performed by three trained examiners who
were not informed of the experimental design to which each monkey was subjected.
Global activity
The video recording files, containing 240 min of recordings for each experimental animal,
were analyzed using video analysis system software that measured GA (Smart 3.0, Panlab S.L., Barcelona, Spain), as previously reported (Khroyan et al., 2007; Otero et al., 2010; Toll et al., 2009 ). This software counted the change rates of all pixels between sequential binary images, which were converted from frames of captured video images with a fixed home cage background (Fig. 1C) . GA was subdivided into three types of activities based on rate of physical movement in cynomolgus monkeys: (1) "high activity": movement of more than 50 cm 2 /s, (2) "low activity": movement between 5 cm 2 /s and 50 cm 2 /s, and (3) "immobility": movement of less than 5 cm 2 /s.
Magnetic resonance imaging (MRI) Protocol
As described in our previous report (Jeong et al., 2018; Yeo et al., 2015; Yi et al., 2017) , the monkeys were initially anesthetized with intramuscular injections of 0.5 mg/kg ketamine (Yuhan, Seoul, South Korea), maintained with 2% isoflurane (Hana Pharmacy, Hwaseong, South Korea) in oxygen at a flow rate 2 L/minute using an anesthesia machine (Royal Medical, Gyeonggi, South Korea) and immobilized in a supine position in a custom-made bed holder during MRI scan.
The level of inhaled CO2, O2 saturation, pulse, respiration rate, and body temperature were monitored continuously; and body temperature was maintained by a warm blanket surrounding the animal. No tracheal intubation was used. All MRI experiments were performed on a Philips
3T Achieva scanner (Philips Medical System, Best, Netherlands) with a 32-channel head coil.
Three-dimensional sagittal T1-weighted images were acquired using a Turbo Field Echo sequence with the following parameters: echo time = 6.7 ms, repetition time = 14 ms, flip angle = 8°, number of signal averages = 4, acquisition matrix = 256 × 256 mm, field of view = 128 × 128 × 75 mm, voxel size = 0.5 × 0.5 × 0.5 mm, number of slices = 150, and slice thickness = 0.5 mm.
Total acquisition time takes 10 min. After the MRI scans, the monkeys recovered from anesthesia and were returned to their cages. Daily monitoring and care were provided to the monkeys by veterinarians (Y.B.J, B.S.K).
Positron emission tomography (PET) imaging protocol
All PET images were acquired using a PET/computed tomography (CT) scanner (nanoScan PET-CT, Mediso Ltd., Budapest, Hungary). PET/CT and MRI were performed in separate days (average interval 3~5 days). Anesthesia was induced and maintained in the same way as MRI.
PET imaging was performed to evaluate DAT (Kazumata et al., 1998) . 18 F-FP-CIT was obtained from a commercial company (DuChemBio Co., Ltd., Daejeon, Korea). Following a CT scan for attenuation correction, 185 MBq 18F-FP-CIT in 1.5 ml saline was injected intravenously via the saphenous vein. PET acquisition of 400 x 400 matrix size in the list mode was concomitantly started with the injection for 120 min following a 39-frame dynamic sequence: 15 s x 8, 30 s x 6, 60 s x 5, 120 s x 5, 300 s x 10, and 600 s x 5. The images were reconstructed using a three-dimensional ordered subsets expectation maximization algorithm (Tera-Tomo, Mediso
Ltd., Hungary), and post-processed using syngo VG51C software (Siemens Medical Solutions, Erlangen, Germany) to visualize multiplanar fusion images. Reconstructed voxel values in each frame were reported in standard uptake value from body weight, corrected for radioactive decay to the time of injection; the voxel dimensions were 0.4 x 0.4 x 0.4 mm 3 . The final three frames corresponding to 90-120 min after injection were used for dynamic analysis because the specific striatal uptake was found to reach maximal value in baseline.
PET/MRI co-registration and image analysis
To fuse the PET and MRI images, all MRI data were processed using the manufacturersupplied software and converted to DICOM format for co-registration with the PET images. Coregistration of the PET and MR images was performed using IRW (Inveon Research Workplace, Siemens Medical Solutions, USA) software by rigid and manual registration (Kim et al., 2013) .
Volumes of interest for the anterior caudate, posterior caudate, anterior putamen, posterior putamen, ventral striatum, globus pallidus internal, globus pallidus external, cerebellum were drawn on co-registered PET/MR images using IRW guided by an atlas (Paxinos et al., 2000) and a delineation protocol (Ballanger et al., 2013) . The binding potential (BP) relative to the concentration of nondisplaceable radioligand in tissue was measured using the cerebellum as a reference region (Logan et al., 1996) .
Tissue preparation
Four animals (C1, C2, C8, C9) were transcardially perfused with 400 ml of 100 mM at room temperature for 1 h. After removal of excess antibodies by TBST washing, specific binding was detected using a chemiluminescence detection system (Thermo Scientific) according to the manufacturer's instructions.
Statistical analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences for Windows, Version, 18.0 (SPSS Inc., Chicago, IL). Results of GA, PET imaging, Western blot analysis, and Parkinsonian behavior scores were analyzed by comparison to the baseline, using a repeated measures ANOVA. Chi-square statistics was used in the comparison GA types. Linear regressions and a two-tailed Pearson's correlation analysis were used to assess the relationships between PET imaging results and GA, Parkinsonian behavior scores, and total doses of MPTP. P < 0.05 was considered statistically significant.
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Results
Homogenous global activity reduction and stable Parkinsonism
To induce a stable and homogenous PD model, individually specified MPTP administration was performed based on the quantification of GA using a video-based analysis system. Because low-dose (0.2 mg/kg) intramuscular injection was repeated continuously until GA was lower than 8% of the baseline, the total dose (2.8-7 mg/kg) and the number of doses (14-35) varied (Table 1, Supplementary Table 1 ). This novel strategy caused statistically significant rates of continuous Parkinsonism from 1 week following the first MPTP administration, according to neurological examinations using Parkinsonian behavior scores (Fig. 2 ). Significant reductions of GA were found from 4 to 48 weeks following the first administration, compared to the baseline (Fig. 3A) . The three types of GA were further analyzed and classified as high activity type, low activity type, or immobility type (Fig. 3B ). Starting at 2 weeks following the first MPTP administration, the percentage of immobility increased significantly compared to the baseline, and it remained elevated until 24 weeks following the first administration. However, the percentage of high activity movement decreased. There were no changes in the saline-treated control group ( Supplementary Fig. 1 ). In contrast, the animal (C6) which was discontinued injections before the threshold was reached recovered to above 70% of baseline at 14 weeks after first administration ( Supplementary Fig. 2) . To verify the availability of GA using a video-based analysis system, the results of GA and Parkinsonian behavior scores were compared using linear regression analysis and two-tailed
A C C E P T E D
Pearson's correlation analysis in all monkeys induced MPTP. There was a negative correlation between GA levels and Parkinsonian behavior scores (Fig. 3C , R 2 = 0.35, P < 0.01).
Continuous decrease of dopamine transporter activity in the striatum
To monitor presynaptic DAT activity in vivo, serial 18 F-FP-CIT PET imaging was performed after MPTP administration. The PET-MRI fusion images for each monkey showed a high specificity in the striatum (Fig. 4A ). Quantitative analysis revealed that the 18 F-FP-CIT BP were significantly reduced in all sub-regions of the striatum at 8, 16, 24, 32, 40 and 48 weeks following the first MPTP administration (Fig. 4B) . In contrast, the animal (C6) recovered to baseline of the 18 F-FP-CIT BP in all sub-regions of the globus pallidus and the striatum without anterior caudate at 16 weeks after first administration. The recovery rate were measured 67-133% of baseline in sub-regions of the striatum and 139-201% of baseline in the globus pallidus ( Supplementary Fig. 3) . (Fig. 5) . A significant positive correlation was observed between GA and the 18 F-FP-CIT BP in all seven sub-regions of the striatum (Fig. 5A , R 2 = 0.39-0.87, P < 0.01).
Monkeys with fewer striatal DAT tended to have lower GA, indicating that a decrease in GA reflects damage in dopaminergic neurons. The caudate and the putamen showed high correlation (R 2 = 0.79-0.87, P < 0.01). With regard to the neurological ratings, there were strong inverse correlations between the Parkinsonian behavior score and the 18 F-FP-CIT BP (Fig. 5B , R 2 = 0.48-0.70, P < 0.01) in all seven sub-regions of the striatum, indicating that the striatal DAT PET data predicts the degree to which Parkinsonian symptoms will occur. No correlations were found between the total dose of MPTP and the 18 F-FP-CIT BP in any time point of the seven sub-regions of the striatum (Fig. 6) . To confirm the damage of dopaminergic neurons in the basal ganglia caused by MPTP, immunohistochemistry and Western blot analysis using the anti-TH antibody were performed.
Histological analysis with 3, 3'-diaminobenzidine staining demonstrated that the TH was reduced by MPTP administration in striatum (Fig. 7A) . Western blot analysis revealed that the TH was significantly reduced by MPTP administration in the putamen and caudate of the striatum and substantia nigra (Fig. 7B) . 
Discussion
This study confirmed that objective and accurate evaluations of the severity of behavioral symptoms can be made using automatic quantification of GA using a video-based analysis system in the identical context of previous study (Liu et al., 2009) . Changes in GA levels indicated the severity of movement disorders induced by MPTP by demonstrating akinesia and bradykinesia.
GA evaluations were not only negatively correlated with scores of Parkinsonian behavior in all monkeys (Fig. 3C , R 2 = 0.35, P < 0.01), but also positively correlated with the 18 F-FP-CIT BP in all seven sub-regions of the striatum (Fig. 5A , R 2 = 0.39-0.87, P < 0.01). Although GA results were limited to the measurement of specific symptoms, rather than evaluation according to a rating scale, the advantage of ensuring consistent results at all times without trained examiners can be useful in the MPTP-induced PD model, which individually shows symptomatic differences.
Our results show that although it may be unclear whether or not GA analysis based on twodimensional images precisely reflects three-dimensional movements of NHPs, GA analysis is adequate in reflecting quantitative changes in movements. We conclude that the measurement error introduced by the omission of one dimension in each individual primate cage is negligible (Supplementary fig. 4 ).
As there are variable susceptibility to systemic MPTP administration in macaques, various intravenous (i.v.) or intramuscular (i.m.) doses were used repeatedly until inducing parkinsonian motor disability of moderate degree and symptoms stabilized (Supplementary Table   2 ). The single dose (MPTP dose administered per injection) had a range from 0.2 to 0.6 mg/kg.
Nevertheless, some monkeys showed recovery by compensatory mechanisms such as serotonin pathway, and it was fatal to other monkeys (Beaudoin-Gobert et al., 2015; Boulet et al., 2008; Lin et al., 2015) . In our study, the single dose of MPTP was determined as 0.2 mg/kg per injection, which is the minimum dose on previous studies. In this dose, Lin, et al. reported that around 50% monkeys were recovered with 1 week interval repetition (Lin et al., 2015) . Taken together, the minimum single dose was repeated with daily interval (Monday to Friday) for inhibiting recovery, and two days (Saturday to Sunday) were given for preventing death.
It is also shown that this method can reinforce previous guidelines for adjustments of MPTP treatment in order to produce stable Parkinsonian symptoms (Potts et al., 2014) . modeling stable symptoms by complementing the weaknesses of the previous motor disability score method. Just as in the case of the previous guidelines study (Potts et al., 2014) , our present study used cynomolgus monkeys that originated from nonselective breeding and had a similar weight and age. However, both the single dose (0.2 mg/kg) and the total cumulative dose (3.88 ± 0.79 mg/kg) in our experiment were lower than the averages presented in the previous guidelines study (reference single dose, 0.6 ± 0.03 mg/kg; total cumulative dose, 5.9 ± 0.4 mg/kg). Our injections was conducted five times a week intramuscularly, compared to the 1-2 week intervals between MPTP intravenous injections in most other cases. Our study suggests that the individual optimum stopping point of repeated low-dose MPTP administration at brief intervals can be individually defined based on GA evaluations that reflect individual severity of symptoms. In the five animals that showed stable symptoms persisting for more than 24 weeks, injections were discontinued when the GA intensity fell below 8% of baseline GA levels. Damage of dopaminergic neuronal systems in the basal ganglia was confirmed by immunohistochemistry, Western blot, and a PET scan after strategic administration of MPTP (Fig. 4, Fig. 6 ). The occurrence of spontaneous recovery was further analyzed in a previous report (Potts et al., 2014) . According to the results, the frequency of recovery in cynomolgus was 38%. However, the adjustments of MPTP treatment based on GA evaluations did not induce spontaneous recovery for more than 48 weeks. In contrast, when we discontinued injections before the threshold was reached, one animal (C6) made a recovery, as made evident by GA evaluations and PET images ( Supplementary Fig. 2, Supplementary Fig. 3 ). Animal C6 showed 53% of baseline GA intensity when MPTP injections were discontinued (Supplementary Table 1 ). Furthermore, the two-fold improvement compared to baseline of the 18 F-FP-CIT BP was measured in the external globus pallidus of the animal (C6) at 16 weeks after first administration ( Supplementary Fig. 3 ). This case could be useful for the discovery of compensatory mechanisms after MPTP administration.
Although the proposed setting of the individual optimum stop point of MPTP injections is limited depending on the results of this study, it is necessary for further studies to increase the measurement time of GA and include a various range of control groups to define a more precise stopping point for MPTP administration.
For preclinical studies, individual injection of different doses of MPTP is intended for stable maintenance of chronic PD symptoms. Previous study have suggested a guideline to assess stability of symptoms for 8 weeks after the last MPTP administration (Potts et al., 2014) .
Based on the results of this study, we also propose to use preclinical studies for animals which maintain behavioral symptoms for 8 weeks after the last administration.
In addition, the severity of Parkinsonian symptoms and the loss rates of DAT in each striatal sub-region did not correlate with the total dose of MPTP, indicating that a fixed MPTP dose is not a good strategy for development of chronic NHP PD models. One animal (C3) needed to be injected 35 times to reach 3% of baseline GA intensity (see Supplementary Table 1 ). On the other hand, another particular animal (C5) presented with severe symptoms and did not manage to eat conventional food (apples, bananas) by itself after 15 injections of MPTP. For this animal to regain its vigor, it was served liquefied formula milk. This aspect is consistent with previous studies that the sensitivity to MPTP differed among monkeys of the same species in previous report (Potts et al., 2014) . These outcomes may be the result of individual immune system differences regarding protective mechanisms against MPTP toxicity. The previous studies have demonstrated that there is considerable heterogeneity in immunological parameters between individuals (Brodin et al., 2015) and that dopaminergic neurons are damaged by the infiltration of T-lymphocytes in SNpc in MPTP model animals and patients with PD (Alberio et al., 2012; Chandra et al., 2016; Pacheco et al., 2009; Roy et al., 2015; Tang et al., 2014) . Because the response to MPTP may vary from individual to individual and some individuals may not be able to eat, it is important to establish care guidelines for acute phase reactions before administering MPTP for the first time. It is also useful to establish care guidelines using the methods we present here.
A C C E P T E D M A N U S C R I P T
Conclusions
This study reinforces previous guidelines regarding production of NHP PD models with stable Parkinsonian symptoms. The novel strategy of MPTP administration based on GA evaluations using a video-based analysis system presented here provides an important conceptual advance of this method for the development of chronic NHP PD models. It further highlights how increasing the efficiency of developing continuously stable NHP PD models is essential to producing more important preclinical research regarding the determination of mechanisms underlying PD pathogenesis and the development of therapeutic agents. Therefore, this strategy to producing stable chronic NHP PD models will contribute to the development of treatment strategies for Parkinson's disease. A C C E P T E D M A N U S C R I P T
